Minding the Pharma Delta Error in the Post-truth World.pdf

Alas, my smartphone seems to evolve more efficiently than I do. What should I do? Strive to be wiser today than yesterday!

1. MINDING THE
DELTA ERROR
Ajaz S. Hussain, Ph.D.
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 1

2. Aiyo, my SMART phone, could develop more
efficiently than I: Wiser today than yesterday?
•Hussain, A.S., Yu, X. & Johnson, R.D. Application of Neural Computing in
Pharmaceutical Product Development. Pharm Res 8, 1248–1252 (1991).
https://doi.org/10.1023/A:1015843527138
•Hussain, A.S. Pharmaceuticals Beyond 2020: Professionals and Artificial intelligence. Pharma Times -Vol. 52 -No. 06 -June 2020.
https://ipapharma.org/3d-flip-
book/pharma-times-june-2020/
•Hussain, A.S. AI-Based Pharmaceutical Formulations and Fraud Detection in Pharma.
INTERPHEX 2024 Sheds Light on Cutting-Edge Solutions: Leveraging AI for Fraud
Detection in Pharma (biopharmaboardroom.com)
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 2
33 Years

3. PHARMA I AND AI
Formulation by design with built -in fraud detector

7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 3

4. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 4
@US FDA 2001-2002 to “One Quality Voice” (2014)
FDA's PAT Team: Shall We Dance? | Process Analytical Technology | Pharmaceutical Manufacturing | Pharma Manufacturing

5. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 5
25 May 2012 Basel, Switzerland. A philosophical exploration - Scientific understanding
and risk-based regulatory decisions on Quality by Design. How good are the scientific
explanations in regulatory submissions? Scientific explanations yield understanding; the
quality of explanations differs. What role can Chemometrics, Pharmacometrics, and
Econometrics play? Understanding multidisciplinary (cGMP, CMC, Clin. Pharm., Tox.,
Clinical, Public Health) perspectives on risk is essential. Opportunities are only when the
disciplinary divides are bridged. Within the regulatory realm, how we set specifications
and assess risk has progressed incrementally; at this rate, Vision 2020 may be expected to
be visible broadly over time by 2020.
Chemometrics, Pharmacometrics and Econometrics
Dimensions_of_Quality by Desing | PPT
(slideshare.net)

6. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 6
Making High Quality Affordable | PPT (slideshare.net)

7. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 7
Twenty years later @ NIPTE

8. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 8
Statistical Thinking and Pharmaceutical Professional Development, a keynote by Ajaz NCB 2023 20 June 2023 | PPT (slideshare.net)

9. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 9

10. INTERPHEX 2024 Sheds Light on Cutting -Edge Solutions: Leveraging AI
for Fraud Detection in Pharma (biopharmaboardroom.com)
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 10

11. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 11

12. Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 7/6/2024 12

13. The Delta
•Between yesterday and today
•Between your expectations and
expected value
•Between a placebo and a
pharmaceutical
•Between efficacy and
effectiveness
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 13

14. 7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 14

15. SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an
Avenger.pdf (slideshare.net); a keynote at the CSF 2024, Boston
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 15

16. 7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 16

17. 7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 17

18. 7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 18

19. Common sense needs to
be a common cause
•The current system for updating and correcting prior
knowledge (as in physicochemical attributes critical to
quality) continues to be neglected even for NTI drugs.
Physicochemical failure modes for Narrow Therapeutic Index (NTI) drugs (europeanpharmaceuticalreview.com)
•The challenge at hand is a “common cause.” problem which we treat as a “special cause” problem
•In this context, the scope of credible AI applications and solutions to formulation development is severely limited (for instance, to certain new developments and green facilities),
Hussain, A.S., Gurvich, V.J. & Morris, K. Pharmaceutical “New Prior Knowledge”: Twenty-First Century Assurance of Therapeutic Equivalence.
AAPS PharmSciTech20, 140 (2019). https://doi.org/10.1208/s12249-019-1347-6
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 19

20. 7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 20

21. Mind the integrity gaps in data and wisdom
•Decades have passed, and legacy knowledge gaps and errors persist. I am worried that we
are not giving enough importance to these gaps and mistakes and that suspicion of
breaches in data integrity [BAD-I] continues to create significant challenges in both
technical and social contexts.
•Let us consider a risk-assessed approach to “reset” to facilitate updating and correcting
prior knowledge locked in past submissions
•Let us focus on applications of AI to gain a holistic systems perspective on pharmaceutical
life cycles
•A common cause strategy that detects, corrects, and prevents fraud and provides a fair and
responsible way to balance maturity and securing humanity.
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 21

22. The Delta
•Between yesterday and today
•Between your expectations and
expected value
•Between a placebo and a
pharmaceutical
•Between efficacy and
effectiveness
"All models are wrong, but some are useful."
7/6/2024Ajaz | Insights for A2Z4.0 Research and Analytics Pvt. Ltd. 22